MedTrace Logo

TNFAIP3 Gene Expression in Ankylosing Spondylitis and Psoriatic Arthritis Patients and Its Relation to Disease Activity

NCT07507487 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2026-04-02

No results posted yet for this study

Summary

1. Identify gene expression of TNFAIP3 in ankylosing spondylitis and psoriatic arthritis patients.
2. Detect relation between TNFAIP3 and disease activity.

Inclusion criteria:

1. Patients diagnosed with ankylosing spondylitis according to Modified New York classification criteria 1984 (10).
2. Patients diagnosed with psoriatic arthritis (PsA patients (age ≥18 years) who fulfilled the CASPAR classification criteria for PsA 2010) (11).

b. Exclusion criteria: Patients with erythrodermic or pustular psoriasis, pregnant and lactating females, patients with autoimmune diseases e.g. systemic lupus erythematosus, or major systemic diseases, and patients receiving any immunosuppressive drug will be excluded from the study.

Conditions

  • Ankylosing Spondylitis and Psoriatic Arthritis Patients

Interventions

DIAGNOSTIC_TEST

Detection of TNFAIP3 gene expression by real time PCR.

Detection of TNFAIP3 gene expression by real time PCR.

Sponsors & Collaborators

  • Assiut University

    collaborator OTHER

  • Asmaa Hassan mohamed Abdel Mawjoud

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-04-30
Primary Completion
2028-12-31
Completion
2029-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07507487 on ClinicalTrials.gov